These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 32774215)

  • 1. Optimal Systemic Treatment for Early Triple-Negative Breast Cancer.
    Furlanetto J; Loibl S
    Breast Care (Basel); 2020 Jun; 15(3):217-226. PubMed ID: 32774215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platinum-based chemotherapy for early triple-negative breast cancer.
    Mason SR; Willson ML; Egger SJ; Beith J; Dear RF; Goodwin A
    Cochrane Database Syst Rev; 2023 Sep; 9(9):CD014805. PubMed ID: 37681577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer: The GeparX 2 × 2 Randomized Clinical Trial.
    Blohmer JU; Link T; Reinisch M; Just M; Untch M; Stötzer O; Fasching PA; Schneeweiss A; Wimberger P; Seiler S; Huober J; Thill M; Jackisch C; Rhiem K; Solbach C; Hanusch C; Seither F; Denkert C; Engels K; Nekljudova V; Loibl S;
    JAMA Oncol; 2022 Jul; 8(7):1010-1018. PubMed ID: 35588050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pembrolizumab in combination with nab-paclitaxel for the treatment of patients with early-stage triple-negative breast cancer - A single-arm phase II trial (NeoImmunoboost, AGO-B-041).
    Fasching PA; Hein A; Kolberg HC; Häberle L; Uhrig S; Rübner M; Belleville E; Hack CC; Fehm TN; Janni W; Hartmann A; Erber R; Theuser AK; Brucker SY; Hartkopf AD; Untch M
    Eur J Cancer; 2023 May; 184():1-9. PubMed ID: 36871424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nab-paclitaxel for the treatment of triple-negative breast cancer: Rationale, clinical data and future perspectives.
    Schettini F; Giuliano M; De Placido S; Arpino G
    Cancer Treat Rev; 2016 Nov; 50():129-141. PubMed ID: 27665540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival outcomes for dose-dense paclitaxel plus carboplatin neoadjuvant vs standard adjuvant chemotherapy in stage II to III triple-negative breast cancer: A prospective cohort study with propensity-matched analysis.
    Xiu M; Zhang P; Wang X; Fan Y; Li Q; Li Q; Wang J; Dong L; Luo Y; Yuan P; Ma F; Xu B
    Int J Cancer; 2022 Aug; 151(4):578-589. PubMed ID: 35403702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRCA Mutation Status in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: A Pivotal Role for Treatment Decision-Making.
    Pavese F; Capoluongo ED; Muratore M; Minucci A; Santonocito C; Fuso P; Concolino P; Di Stasio E; Carbognin L; Tiberi G; Garganese G; Corrado G; Di Leone A; Generali D; Fragomeni SM; D'Angelo T; Franceschini G; Masetti R; Fabi A; Mulè A; Santoro A; Belli P; Tortora G; Scambia G; Paris I
    Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platelet-to-Lymphocyte Ratio Is Associated With Favorable Response to Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: A Study on 120 Patients.
    Lusho S; Durando X; Mouret-Reynier MA; Kossai M; Lacrampe N; Molnar I; Penault-Llorca F; Radosevic-Robin N; Abrial C
    Front Oncol; 2021; 11():678315. PubMed ID: 34367964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study.
    Loibl S; Untch M; Burchardi N; Huober J; Sinn BV; Blohmer JU; Grischke EM; Furlanetto J; Tesch H; Hanusch C; Engels K; Rezai M; Jackisch C; Schmitt WD; von Minckwitz G; Thomalla J; Kümmel S; Rautenberg B; Fasching PA; Weber K; Rhiem K; Denkert C; Schneeweiss A
    Ann Oncol; 2019 Aug; 30(8):1279-1288. PubMed ID: 31095287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant and Neoadjuvant Treatment of Triple-Negative Breast Cancer With Chemotherapy.
    Marra A; Curigliano G
    Cancer J; 2021 Jan-Feb 01; 27(1):41-49. PubMed ID: 33475292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II Trial of Neoadjuvant Carboplatin and Nab-Paclitaxel in Patients with Triple-Negative Breast Cancer.
    Yuan Y; Lee JS; Yost SE; Li SM; Frankel PH; Ruel C; Schmolze D; Robinson K; Tang A; Martinez N; Stewart D; Waisman J; Kruper L; Jones V; Menicucci A; Uygun S; Yoder E; van der Baan B; Yim JH; Yeon C; Somlo G; Mortimer J
    Oncologist; 2021 Mar; 26(3):e382-e393. PubMed ID: 33098195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of platinum-based chemotherapy on the prognosis of early triple-negative breast cancer: a systematic review and meta-analysis.
    Zhao F; Shen G; Dong Q; Xin Y; Huo X; Wang M; Liu Z; Zhao Y; Ren D; Xie Q; Liu Z; Li Z; Gao L; Du F; Zhao J
    Clin Exp Med; 2023 Oct; 23(6):2025-2040. PubMed ID: 36422737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overview of resistance to systemic therapy in patients with breast cancer.
    Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
    Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triple negative breast cancer and platinum-based systemic treatment: a meta-analysis and systematic review.
    Pandy JGP; Balolong-Garcia JC; Cruz-Ordinario MVB; Que FVF
    BMC Cancer; 2019 Nov; 19(1):1065. PubMed ID: 31703646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant Chemotherapy Considerations in Triple-Negative Breast Cancer.
    McAndrew N; DeMichele A
    J Target Ther Cancer; 2018 Feb; 7(1):52-69. PubMed ID: 29577076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current strategy for triple-negative breast cancer: appropriate combination of surgery, radiation, and chemotherapy.
    Yagata H; Kajiura Y; Yamauchi H
    Breast Cancer; 2011 Jul; 18(3):165-73. PubMed ID: 21290263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant therapy in triple-negative breast cancer: A systematic review and network meta-analysis.
    Lin YY; Gao HF; Yang X; Zhu T; Zheng XX; Ji F; Zhang LL; Yang CQ; Yang M; Li JQ; Cheng MY; Wang K
    Breast; 2022 Dec; 66():126-135. PubMed ID: 36265208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The advance of adjuvant treatment for triple-negative breast cancer.
    Ge J; Zuo W; Chen Y; Shao Z; Yu K
    Cancer Biol Med; 2021 Aug; 19(2):187-201. PubMed ID: 34448553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early Triple Negative Breast Cancer: Conventional Treatment and Emerging Therapeutic Landscapes.
    Diana A; Carlino F; Franzese E; Oikonomidou O; Criscitiello C; De Vita F; Ciardiello F; Orditura M
    Cancers (Basel); 2020 Mar; 12(4):. PubMed ID: 32235297
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.